175 related articles for article (PubMed ID: 35606354)
1. p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis.
Solé L; Lobo-Jarne T; Álvarez-Villanueva D; Alonso-Marañón J; Guillén Y; Guix M; Sangrador I; Rozalén C; Vert A; Barbachano A; Lop J; Salido M; Bellosillo B; García-Romero R; Garrido M; González J; Martínez-Iniesta M; López-Arribillaga E; Salazar R; Montagut C; Torres F; Iglesias M; Celià-Terrassa T; Muñoz A; Villanueva A; Bigas A; Espinosa L
Nat Commun; 2022 May; 13(1):2866. PubMed ID: 35606354
[TBL] [Abstract][Full Text] [Related]
2. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.
Inoue A; Robinson FS; Minelli R; Tomihara H; Rizi BS; Rose JL; Kodama T; Srinivasan S; Harris AL; Zuniga AM; Mullinax RA; Ma X; Seth S; Daniele JR; Peoples MD; Loponte S; Akdemir KC; Khor TO; Feng N; Roszik J; Sobieski MM; Brunell D; Stephan C; Giuliani V; Deem AK; Shingu T; Deribe YL; Menter DG; Heffernan TP; Viale A; Bristow CA; Kopetz S; Draetta GF; Genovese G; Carugo A
Gastroenterology; 2021 Jul; 161(1):196-210. PubMed ID: 33745946
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors.
Li H; Zhang J; Tong JHM; Chan AWH; Yu J; Kang W; To KF
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795192
[TBL] [Abstract][Full Text] [Related]
4. Modeling the Etiology of p53-mutated Cancer Cells.
Perez RE; Shen H; Duan L; Kim RH; Kim T; Park NH; Maki CG
J Biol Chem; 2016 May; 291(19):10131-47. PubMed ID: 27022024
[TBL] [Abstract][Full Text] [Related]
5. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
6. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
[TBL] [Abstract][Full Text] [Related]
7. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients.
Hassin O; Nataraj NB; Shreberk-Shaked M; Aylon Y; Yaeger R; Fontemaggi G; Mukherjee S; Maddalena M; Avioz A; Iancu O; Mallel G; Gershoni A; Grosheva I; Feldmesser E; Ben-Dor S; Golani O; Hendel A; Blandino G; Kelsen D; Yarden Y; Oren M
Nat Commun; 2022 May; 13(1):2800. PubMed ID: 35589715
[TBL] [Abstract][Full Text] [Related]
8. LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation.
Zeng K; Chen X; Hu X; Liu X; Xu T; Sun H; Pan Y; He B; Wang S
Oncogene; 2018 Oct; 37(41):5534-5551. PubMed ID: 29899406
[TBL] [Abstract][Full Text] [Related]
9. The chromatin remodelling component SMARCB1/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22.
Pancione M; Remo A; Zanella C; Sabatino L; Di Blasi A; Laudanna C; Astati L; Rocco M; Bifano D; Piacentini P; Pavan L; Purgato A; Greco F; Talamini A; Bonetti A; Ceccarelli M; Vendraminelli R; Manfrin E; Colantuoni V
J Transl Med; 2013 Nov; 11():297. PubMed ID: 24286138
[TBL] [Abstract][Full Text] [Related]
10. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.
Manic G; Signore M; Sistigu A; Russo G; Corradi F; Siteni S; Musella M; Vitale S; De Angelis ML; Pallocca M; Amoreo CA; Sperati F; Di Franco S; Barresi S; Policicchio E; De Luca G; De Nicola F; Mottolese M; Zeuner A; Fanciulli M; Stassi G; Maugeri-Saccà M; Baiocchi M; Tartaglia M; Vitale I; De Maria R
Gut; 2018 May; 67(5):903-917. PubMed ID: 28389531
[TBL] [Abstract][Full Text] [Related]
11. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
12. P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.
Li XL; Zhou J; Chen ZR; Chng WJ
World J Gastroenterol; 2015 Jan; 21(1):84-93. PubMed ID: 25574081
[TBL] [Abstract][Full Text] [Related]
13. A selective p53 activator and anticancer agent to improve colorectal cancer therapy.
Ramos H; Soares MIL; Silva J; Raimundo L; Calheiros J; Gomes C; Reis F; Monteiro FA; Nunes C; Reis S; Bosco B; Piazza S; Domingues L; Chlapek P; Vlcek P; Fabian P; Rajado AT; Carvalho ATP; Veselska R; Inga A; Pinho E Melo TMVD; Saraiva L
Cell Rep; 2021 Apr; 35(2):108982. PubMed ID: 33852837
[TBL] [Abstract][Full Text] [Related]
14. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
15. Cyclophilin B induces chemoresistance by degrading wild-type p53 via interaction with MDM2 in colorectal cancer.
Choi TG; Nguyen MN; Kim J; Jo YH; Jang M; Nguyen NNY; Yun HR; Choe W; Kang I; Ha J; Tang DG; Kim SS
J Pathol; 2018 Sep; 246(1):115-126. PubMed ID: 29876924
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone I induces human colorectal cancer cell apoptosis: The potential roles of Aurora A-p53 and survivin-mediated signaling pathways.
Lu M; Wang C; Wang J
Int J Oncol; 2016 Aug; 49(2):603-10. PubMed ID: 27279458
[TBL] [Abstract][Full Text] [Related]
17. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
[TBL] [Abstract][Full Text] [Related]
18. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
19. FOXD3, frequently methylated in colorectal cancer, acts as a tumor suppressor and induces tumor cell apoptosis under ER stress via p53.
Xu M; Zhu J; Liu S; Wang C; Shi Q; Kuang Y; Fang X; Hu X
Carcinogenesis; 2020 Sep; 41(9):1253-1262. PubMed ID: 31784734
[TBL] [Abstract][Full Text] [Related]
20. Butyrate supplementation regulates expression of chromosome segregation 1‑like protein to reverse the genetic distortion caused by p53 mutations in colorectal cancer.
Chang CC; Kao WY; Liu CY; Su HH; Kan YA; Lin PY; Ku WC; Chang KW; Yang RN; Huang CJ
Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35417036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
